An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Trial Status: active
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety,
pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or
metastatic solid tumors with a KRAS G12C mutation.
Inclusion Criteria
Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation.
Women of childbearing potential must agree to remain abstinent or use contraception, and agree to refrain from donating eggs during the treatment period and after the final dose of study treatment as specified in the protocol.
Men who are not surgically sterile must agree to remain abstinent or use a condom, and agreement to refrain from donating sperm during the treatment period and after the final dose of study treatment as specified in the protocol.
Exclusion Criteria
Active brain metastases.
Malabsorption or other condition that interferes with enteral absorption.
Clinically significant cardiovascular dysfunction or liver disease.
Additional locations may be listed on ClinicalTrials.gov for NCT04449874.
